Depo-Medrol warning tops OSN’s news of the week

Here are some of the top stories on Healio.com/OSN in the past week:

 

Remove Depo-Medrol from ophthalmological surgical suites to avoid accidental retinal toxicity

Methylprednisolone acetate, which has similar packaging and appearance to triamcinolone acetonide, should be removed from shelves of ophthalmological surgical suites because intraocular use can lead to irreversible retinal necrosis and permanent vision loss. Read more.

 

FDA places clinical hold on IND application for Adverums wet AMD gene therapy

The FDA has placed a clinical hold on Adverum Biotechnologies’ investigational new drug application for its gene therapy candidate for wet age-related macular degeneration until it receives further information regarding the company’s manufacturing process. Read more.

 

Bees in the eye? Avoiding ocular injuries from dirt, debris and insects

A doctor at Fooyin Hospital in Taiwan recently described pulling four bees out of the eye of a patient who was complaining of extreme pain, swelling and tearing. Read more.

 

Partners named for childrens vision and eye health program

The Better Vision Together – Community of Practice program from the National Center for Children’s Vision and Eye Health at Prevent Blindness has its first partners. Read more.

 

Visual acuity gains reported in phase 3 trial of Leber hereditary optic neuropathy treatment

GenSight Biologics’ gene therapy treatment candidate for Leber hereditary optic neuropathy showed continuous recovery of visual function in a phase 3 trial. Read more.

Here are some of the top stories on Healio.com/OSN in the past week:

 

Remove Depo-Medrol from ophthalmological surgical suites to avoid accidental retinal toxicity

Methylprednisolone acetate, which has similar packaging and appearance to triamcinolone acetonide, should be removed from shelves of ophthalmological surgical suites because intraocular use can lead to irreversible retinal necrosis and permanent vision loss. Read more.

 

FDA places clinical hold on IND application for Adverums wet AMD gene therapy

The FDA has placed a clinical hold on Adverum Biotechnologies’ investigational new drug application for its gene therapy candidate for wet age-related macular degeneration until it receives further information regarding the company’s manufacturing process. Read more.

 

Bees in the eye? Avoiding ocular injuries from dirt, debris and insects

A doctor at Fooyin Hospital in Taiwan recently described pulling four bees out of the eye of a patient who was complaining of extreme pain, swelling and tearing. Read more.

 

Partners named for childrens vision and eye health program

The Better Vision Together – Community of Practice program from the National Center for Children’s Vision and Eye Health at Prevent Blindness has its first partners. Read more.

 

Visual acuity gains reported in phase 3 trial of Leber hereditary optic neuropathy treatment

GenSight Biologics’ gene therapy treatment candidate for Leber hereditary optic neuropathy showed continuous recovery of visual function in a phase 3 trial. Read more.